We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Traitement de maintenance des lymphomes malins non hodgkiniens.
- Authors
Pascal, L.; Terriou, L.; Morschhauser, F.
- Abstract
Maintenance treatment aims to sustain the response of induction chemotherapy, reduce the relapse rate, and provide a longer progression-free survival and time to the next course of chemotherapy. It must have an acceptable toxicity profile in order to obtain the trust of both patient and physician over the long term; it must maintain the patient in remission. An ideal maintenance treatment would be effective as monotherapy, with minimal side effects in the short and long term, and easy to administer, requiring minimal supervision. Different drugs are used for non-hodgkin lymphoma, but the results are sometimes controversial; the first was interferon alpha, which is not a standard treatment. More recently, rituximab has demonstrated a significant improvement in progression-free survival, but no improvement in overall survival in the treatment of follicular NHL. The PRIMA study confirms this data: progression-free survival at 3 years was 75% (against 58% in the control arm). So, rituximab can be used as standard maintenance therapy. Other molecules are also developed for this purpose, such as enzastaurin and lenalidomide, for which we do not yet have a definitive evaluation.
- Subjects
LYMPHOMA treatment; CANCER chemotherapy; TUMOR prognosis; RITUXIMAB; THALIDOMIDE; INTERFERONS; TREATMENT effectiveness
- Publication
Oncologie (Tech Science Press), 2011, Vol 13, Issue 9, p543
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-011-2062-4